Methotrexate inhibits the first committed step of purine biosynthesis in mitogen-stimulated human T-lymphocytes: a metabolic basis for efficacy in rheumatoid arthritis?
The immunosuppressive and anti-inflammatory effects of low-dose methotrexate (MTX) have been related directly to inhibition of folate-dependent enzymes by polyglutamated derivatives, or indirectly to adenosine release and/or apoptosis and clonal deletion of activated peripheral blood lymphocytes in S-phase. In this study of phytohaemagglutinin-stimulated primary human T-lymphocytes we show that MTX (20 nM to 20 microM) was cytostatic not cytotoxic, halting proliferation at G(1). This stasis of blastogenesis was associated with an inhibition of purine ribonucleotide synthesis but a stimulation of pyrimidine biosynthesis, the normal mitogen-induced expansion of ATP and GTP pools over 72 h being restricted to concentrations of unstimulated T-cells, whereas the increment in UTP pools exceeded that of controls. Decreased incorporation of H(14)CO(3) or [(14)C]glycine into purine ribonucleotides, with no radiolabel accumulation in any de novo synthetic intermediate but enhanced H(14)CO(3) incorporation into UTP, supported these MTX-related effects. Exaggerated [(14)C]hypoxanthine salvage (which normalized the purine and UTP pools) confirmed the increased availability of 5-phosphoribosyl-1-pyrophosphate (PP-ribose-P) as the molecular mechanism underlying these disparate changes. These results provide the first substantive evidence that the immunosuppressive effects of low-dose MTX in primary blasting human T-lymphocytes relate not to the inhibition of the two folate-dependent enzymes of purine biosynthesis but to inhibition of the first enzyme, amidophosphoribosyltransferase, thereby elevating PP-ribose-P and stimulating UTP synthesis. Varying cell types or incubation conditions employed by other workers, especially malignant/activated cells with high basal metabolic rates, might mask the effects noted in primary human T-lymphocytes. The findings imply the involvement of low-dose MTX in the inhibition of T-lymphocyte proliferation and proliferation-dependent processes in rheumatoid arthritis.
Fairbanks
L D
LD
Purine Research Laboratory, 5th Floor Thomas Guy House, GKT Guy's Hospital, London Bridge, London SE1 9RT, U.K.
Rückemann
K
K
Qiu
Y
Y
Hawrylowicz
C M
CM
Richards
D F
DF
Swaminathan
R
R
Kirschbaum
B
B
Simmonds
H A
HA
D000582:Amidophosphoribosyltransferase / Q000378:metabolism; D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000276:immunology / Q000378:metabolism* / Q000473:pathology; D001639:Bicarbonates / Q000378:metabolism; D002453:Cell Cycle / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D004305:Dose-Response Relationship, Drug; D005998:Glycine / Q000378:metabolism; D006801:Humans; D019271:Hypoxanthine / Q000378:metabolism; D007166:Immunosuppressive Agents / Q000494:pharmacology* / Q000627:therapeutic use; D008213:Lymphocyte Activation; D008727:Methotrexate / Q000494:pharmacology* / Q000627:therapeutic use; D009711:Nucleotides / Q000378:metabolism; D010754:Phosphoribosyl Pyrophosphate / Q000378:metabolism; D010835:Phytohemagglutinins / Q000037:antagonists & inhibitors / Q000494:pharmacology; D014176:Protein Biosynthesis; D011506:Proteins / Q000032:analysis; D011687:Purines / Q000096:biosynthesis* / Q000378:metabolism; D011743:Pyrimidines / Q000096:biosynthesis / Q000378:metabolism; D012265:Ribonucleotides / Q000096:biosynthesis / Q000378:metabolism; D013601:T-Lymphocytes / Q000166:cytology / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism; D014529:Uridine / Q000378:metabolism
D001639:Bicarbonates; D007166:Immunosuppressive Agents; D009711:Nucleotides; D010835:Phytohemagglutinins; D011506:Proteins; D011687:Purines; D011743:Pyrimidines; D012265:Ribonucleotides; D019271:Hypoxanthine; D010754:Phosphoribosyl Pyrophosphate; D000582:Amidophosphoribosyltransferase; D005998:Glycine; D014529:Uridine; D008727:Methotrexate